These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 1868247)

  • 1. Administration of erythropoietin to patients with beta-thalassemia intermedia: a preliminary trial.
    Rachmilewitz EA; Goldfarb A; Dover G
    Blood; 1991 Aug; 78(4):1145-7. PubMed ID: 1868247
    [No Abstract]   [Full Text] [Related]  

  • 2. Trial of recombinant human erythropoietin: three patients with thalassemia intermedia.
    Olivieri NF; Freedman MH; Perrine SP; Dover GJ; Sheridan B; Essentine DL; Nagel RL
    Blood; 1992 Dec; 80(12):3258-60. PubMed ID: 1467532
    [No Abstract]   [Full Text] [Related]  

  • 3. Serum transferrin receptor levels in patients with thalassemia intermedia during rHuEPO administration.
    Dore F; Bonfigli S; Gaviano E; Pardini S; Longinotti M
    Haematologica; 1996; 81(1):37-9. PubMed ID: 8900849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antierythropoietin antibodies in thalassemia patients.
    Voulgari PV; Chaidos A; Tzouvara E; Alymara V; Alamanos Y; Drosos AA; Bourantas KL
    Ann Hematol; 2004 Jan; 83(1):22-7. PubMed ID: 14530877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human erythropoietin trial in thalassemia intermedia.
    Nişli G; Kavakli K; Vergin C; Oztop S; Cetingül N
    J Trop Pediatr; 1996 Dec; 42(6):330-4. PubMed ID: 9009557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of mouse beta-thalassemia by recombinant human erythropoietin.
    Leroy-Viard K; Rouyer-Fessard P; Beuzard Y
    Blood; 1991 Sep; 78(6):1596-602. PubMed ID: 1884025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low doses of rHuEPO administered to adult patients with thalassemia intermedia.
    Dore F; Gaviano E; Bonfigli S; Pardini S; Pistidda P; Guiso L; Longinotti M
    Ann Hematol; 1994 Oct; 69(4):211-2. PubMed ID: 7948309
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of L-carnitine administration on erythropoietin use in thalassemic minor haemodialysis patients.
    Di Iorio BR; Guastaferro P; Cillo N; Cucciniello E; Bellizzi V
    Nephrol Dial Transplant; 2007 Mar; 22(3):954-5; author reply 955-6. PubMed ID: 17132710
    [No Abstract]   [Full Text] [Related]  

  • 9. Preliminary results with administration of recombinant human erythropoietin in sickle cell/beta-thalassemia patients during pregnancy.
    Bourantas K; Makrydimas G; Georgiou J; Tsiara S; Lolis D
    Eur J Haematol; 1996 May; 56(5):326-8. PubMed ID: 8641410
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of recombinant human erythropoietin in the treatment of thalassemia.
    Rachmilewitz EA; Aker M
    Ann N Y Acad Sci; 1998 Jun; 850():129-38. PubMed ID: 9668535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of recombinant erythropoietin in thalassemic patients on dialysis.
    Lai KN; Wong KC; Li PK; Lui SF
    Am J Kidney Dis; 1992 Mar; 19(3):239-45. PubMed ID: 1553968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial effect of recombinant human erythropoietin in beta thalassaemia patients on dialysis.
    Cozma G; Cozma MC; Mattes U
    Nephrol Dial Transplant; 1992; 7(1):82-3. PubMed ID: 1316587
    [No Abstract]   [Full Text] [Related]  

  • 13. Administration of high doses of recombinant human erythropoietin to patients with beta-thalassemia intermedia: a preliminary trial.
    Bourantas K; Economou G; Georgiou J
    Eur J Haematol; 1997 Jan; 58(1):22-5. PubMed ID: 9020369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiotherapy combined with erythropoietin for the treatment of extramedullary hematopoiesis in an alloimmunized patient with thalassemia intermedia.
    Cianciulli P; Sorrentino F; Morino L; Massa A; Sergiacomi GL; Donato V; Amadori S
    Ann Hematol; 1996 Jun; 72(6):379-81. PubMed ID: 8767108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Termination of transfusion dependence in beta-thalassemia: two-year experience with recombinant human erythropoietin.
    Nişli G; Kavakli K; Aydinok Y; Oztop S; Cetingül N
    Pediatr Hematol Oncol; 1997; 14(3):285-7. PubMed ID: 9185215
    [No Abstract]   [Full Text] [Related]  

  • 16. Therapeutic superiority and safety of combined hydroxyurea with recombinant human erythropoietin over hydroxyurea in young β-thalassemia intermedia patients.
    Elalfy MS; Adly AA; Ismail EA; Elhenawy YI; Elghamry IR
    Eur J Haematol; 2013 Dec; 91(6):522-33. PubMed ID: 23927461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic manipulation of fetal hemoglobin. Update on clinical trials with hydroxyurea.
    Dover GJ
    Ann N Y Acad Sci; 1990; 612():184-90. PubMed ID: 1705407
    [No Abstract]   [Full Text] [Related]  

  • 18. Serum erythropoietin levels in thalassemia intermedia.
    Dore F; Bonfigli S; Gaviano E; Pardini S; Cianciulli P; Papa G; Longinotti M
    Ann Hematol; 1993 Oct; 67(4):183-6. PubMed ID: 8218539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxyurea therapy in thalassemia.
    Loukopoulos D; Voskaridou E; Stamoulakatou A; Papassotiriou Y; Kalotychou V; Loutradi A; Cozma G; Tsiarta H; Pavlides N
    Ann N Y Acad Sci; 1998 Jun; 850():120-8. PubMed ID: 9668534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules.
    Chaidos A; Makis A; Hatzimichael E; Tsiara S; Gouva M; Tzouvara E; Bourantas KL
    Acta Haematol; 2004; 111(4):189-95. PubMed ID: 15153710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.